24 unchanged sentences
Recent Sales of Unregistered Equity Securities
−Removed: In November 2019, we entered into an exchange agreement (the “Exchange Agreement”) with entities affiliated with Biotechnology Value Fund, L.P.
−Removed: (the “Exchanging Stockholders”), pursuant to which we exchanged an aggregate of 1,458,000 shares of our common stock owned by the Exchanging Stockholders for warrants (the “Exchange
−Removed: Warrants”) to purchase an aggregate of 1,458,000 shares of common stock (subject to adjustment in the event of stock splits, recapitalizations and other similar events affecting common stock), with an exercise price of $0.0001 per share.
−Removed: The Exchange Warrants were issued without registration under the Securities Act of 1933, as amended (the “Securities Act”), in reliance on the exemption from registration contained in Section 3(a)(9) of the Securities Act.
−Removed: The Exchanging Stockholders exercised the Exchange Warrants pursuant to a cashless exercise on September 20, 2021 and we issued an aggregate of 1,457,947 shares of common stock to such Exchanging Stockholders.
Issuer Purchases of Equity Securities by the Issuer and Affiliated Purchasers
−Removed: Selected Financial Data
−Removed: You should read the following selected financial data together with the information under “Item 7.
−Removed: Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our consolidated financial statements and related notes included in Part II, Item 8 of this Annual Report on Form 10 K.
−Removed: The selected consolidated statement of operations data for each of the years ended December 31, 2021, 2020 and 2019 and the consolidated balance sheet data as of December 31, 2021 and 2020 are derived from our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K.
−Removed: The consolidated statement of operations data for the years ended December 31, 2018 and 2017 and the consolidated balance sheet data as of December 31, 2019, 2018 and 2017 are derived from our audited consolidated financial statements which are not included in this Annual Report on Form 10-K.
−Removed: Our historical results of any prior periods are not necessary indicative of results to be expected in any future period.
−Removed: Year Ended December 31,
−Removed: Consolidated Statements of Operations and Comprehensive Loss Data:
−Removed: (In thousands, except share and per share amounts)
−Removed: Operating expenses:
−Removed: Research and development
−Removed: General and administrative
−Removed: Total operating expenses
−Removed: Loss from operations
−Removed: Interest income and other expense, net.
−Removed: Gain on deconsolidation of Angel Pharmaceuticals
−Removed: Sublease income - related party
−Removed: Loss from equity method investment
−Removed: Net loss per share, basic and diluted
−Removed: Shares used to compute net loss per share, basic and diluted
−Removed: Other comprehensive income (loss):
−Removed: Unrealized gain (loss) on marketable securities
−Removed: Cumulative foreign currency translation adjustment
−Removed: Comprehensive loss
−Removed: Year Ended December 31,
−Removed: Consolidated Balance Sheet Data:
−Removed: (In thousands)
−Removed: Cash, cash equivalents and marketable securities
−Removed: Working capital
−Removed: Convertible preferred stock
−Removed: Total stockholders’ equity
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.